At present, we are on the Phase III Clinical Trial (Mineral Study1) for the final development of NEUROASPIS PLP10. This is a multi-center double-blind placebo controlled study with three clinical sites in Greece and one in Cyprus, with 220 patients enrolled in the clinical study.

Currently, PALUPA Medical is preparing a protocol for the investigation of efficacy of the NEUROASPIS PLP10 for the Parkinson's decease.


1 ISRCTN06166891 DOI 10.1186/ISRCTN06166891, MINERAL (Magnetic-resonance Image of Nutraceutical Efficacy on Relapsing-ms Autoimmune Lesions) study: a novel nutraceutical formula PLP10 for the treatment of relapsing-remitting multiple sclerosis.